Susan Kline, MD, MPH

After graduating from the University of Minnesota Medical School in 1988, Dr. Kline completed her Internal Medicine residency at the University of Minnesota Medical Center and its affiliated sites. Following completion of her residency she worked in General Internal Medicine and Emergency Medicine for one year at the University of Minnesota Medical Center. She then began her Infectious Disease Fellowship at the University of Minnesota Medical Center and affiliated sites. She also completed her Masters in Public Health during her ID fellowship with an emphasis in Infectious Disease Epidemiology. Dr. Kline then for joined the Internal Medicine faculty in 1994 and is currently a Professor. In addition she has been the Medical Director for Infection Control at the University of Minnesota Medical Center since 1996. She helped establish the Antibiotic Management Team at the University of Minnesota Medical Center in 2007. She currently is the Co-Director of the General Infectious Disease service and the Physician Director of Antimicrobial Management for the ID Division. She also is Co-Director of the HIV Family Clinic in the Delaware Street Clinic. She is the Hospital Epidemiologists for the University of Minnesota Medical Center.

• Minnesota Monthly 2020 Top Doctors
• Minneapolis/St. Paul Business Journal 2021 Healthcare Heros 
• Best Doctors in America® (2011-2012)
• Recipient of Department of Medicine Clinical Excellence Award (September, 2009)
• Alpha Omega Alpha Medical Society–University of Minnesota Medical School (1987)
• Delta Omega Honorary Public Health Society 1995
• Faculty Clinical Excellence Award, Department of Medicine, University of Minnesota (2004, 2009)

• Medical Director of Infection Control, University of Minnesota Health
• Fellow, Society of Hospital Epidemiologists of America (2010)
• Member, Infectious Disease Society of America (IDSA) (1994-present)

• Joshua M Thiede 1 2, Abigail R Gress 1 2, Samuel D Libby 1 2, Christine E Ronayne 1 2, William E Matchett 2 3, Brooke Noren 4, Joanne L Billings 4, Vineet D Menachery 5, Ryan A Langlois 2 3, Susan Kline 1, Tyler D Bold 1 2. Immune profiling reveals early disease trajectories associated with COVID-19 mortality: a sub-study from the ACTT-1 trial. J Infect Dis. 2021 Jan 21;jiab035. doi: 10.1093/infdis/jiab035. Online ahead of print. PMID: 33476387 PMCID: PMC7928927 DOI: 10.1093/infdis/jiab035.
  Contribution: I was the site PI for the University of Minnesota study site for recruitment and enrollment of participants in the ACTT-1 study. I also participated I writing and editing the paper prior to submission of the article.
• Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8. PMID: 32445440 PMCID: PMC7262788 DOI: 10.1056/NEJMoa2007764
  Contribution: I was the site PI for the University of Minnesota study site for recruitment and enrollment of participants in the ACTT study. I was in the writing group for the NEJM article.
• Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Goepfert P, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020 Dec 11:NEJMoa2031994. doi: 10.1056/NEJMoa2031994. Online ahead of print. PMID: 33306283
  Contribution: I was the site PI for the University of Minnesota study site for recruitment and enrollment of participants in the ACTT study. I was in the writing group for the NEJM article.
• Demmer RT, Ulrich A, Wiggen T, Strickland A, Naumchik B, Kulasingam S, Stovitz SD, Marotz C, Belda-Ferre P, Humphrey G, De Hoff P, Laurent L, Kline S, Knight R. SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers. medRxiv. 2020 Aug 5:2020.07.31.20166066. doi: 10.1101/2020.07.31.20166066. Preprint. PMID: 3279392. Accepted for publication ICHE.
  Contribution: I was an invited clinical expert who served a consultant to this group as they designed and implemented their study. I was in the writing group as well.
• Lim S, DeBruin D, Leider JP, Sederstrom N, Lynfield R, Baker JV, Kline S, Kesler S, Rizza S, Wu J, Sharp RR, Wolf SM. Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic. Mayo Clin Proc. 2020 Jun 20 doi: 10.1016/j.mayocp.2020.06.016 [Epub ahead of print]. PMCID: PMC7305893
  Contribution: I was an invited clinical expert who served on the Minnesota Dept of Health work group to set statewide fair distribution standards for EUA remdesivir. This is a manuscript we co-wrote regarding the ethical framework our group developed.
• Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members.Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020 May 22:NEJMoa2007764. doi: 10.1056/NEJMoa2007764. Online ahead of print. PMID: 32445440
  Contribution: I was the site PI for the University of Minnesota study site for recruitment and enrollment of participants in the ACTT study. I was in the writing group for the NEJM article.